Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03395639 · ClinicalTrials.gov registry record · Phase 3
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 168
- Enrollment target
NCT03395639 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 168 participants.
The verdict
NCT03395639, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 168 participants
- Enrollment target
Study Summary
A committee will judge the safety and effectiveness of edoxaban and the regular treatment (standard of care). All children in the study will receive free treatment. They will have a 2 in 3 chance to receive edoxaban, and a 1 in 3 chance to receive the standard of care for preventing blood clots. The study will find out if edoxaban is safer and more effective than the standard of care.
Interventions
- DRUG Standard of Care (SOC)
- DRUG Edoxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2018-05-15 |
| Est. Completion | 2021-12-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03395639
The ClinicalTrials.gov registry entry for NCT03395639 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care (SOC) is the first listed.
NCT03395639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03395639 about?
NCT03395639 is a clinical study titled "Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease". A committee will judge the safety and effectiveness of edoxaban and the regular treatment (standard of care). All children in the study will receive free treatment. They will have a 2 in 3 chance to receive edoxaban, and a 1 in 3 chance to receive the standard of care for preventing blood clots. T...
What is the current status of trial NCT03395639?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 168 participants. The study started on 2018-05-15. Estimated completion is 2021-12-03.
What interventions are being tested in trial NCT03395639?
The interventions under investigation include: Standard of Care (SOC) (DRUG), Edoxaban (DRUG).
Who is sponsoring clinical trial NCT03395639?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.